Injectable vs Oral GLP-1: Which Is Right for You?

Your doctor has recommended a GLP-1 medication. Now you're facing a follow-up question most people don't expect: inject it or swallow it? Injectables dominate both clinical trial evidence and telehealth provider formularies. Oral options do exist — Rybelsus is FDA-approved, and oral compounded semaglutide is available through select providers — but each format carries real trade-offs. This guide walks through injectable vs oral GLP-1 options so you can make an informed decision with your healthcare provider.

The injectable options

Weekly subcutaneous injections are the standard delivery method for GLP-1 medications. "Subcutaneous" means the injection goes into fat just under the skin, not into a vein or muscle. The needle is thin and short, and most patients report minimal discomfort after the first few weeks.

Brand-name injectables come in pre-filled auto-injector pens:

• Wegovy (semaglutide 2.4mg, Novo Nordisk) — FDA-approved for chronic weight management
• Ozempic (semaglutide 0.5mg–2mg, Novo Nordisk) — FDA-approved for type 2 diabetes, frequently prescribed off-label for weight loss
• Zepbound (tirzepatide, Eli Lilly) — FDA-approved for chronic weight management
• Mounjaro (tirzepatide, Eli Lilly) — FDA-approved for type 2 diabetes, prescribed off-label for weight loss

With a pre-filled pen, there's no measuring or loading. You dial the dose, press the pen against your skin, and click. Many patients describe the process as easier than they expected.

Compounded injectable semaglutide uses the same active ingredient as Wegovy and Ozempic but is not FDA-approved as a finished product. It's typically supplied as a multi-dose vial, which you draw into a syringe before injecting. This adds a step that requires some practice, though most patients get comfortable with it quickly.

The clinical evidence for injectable semaglutide is extensive. A major NEJM trial found that weekly subcutaneous semaglutide 2.4mg may reduce body weight by approximately 15% over 68 weeks in adults with obesity, compared to about 2.4% with placebo (Wilding et al., NEJM, 2021). No equivalent large-scale trials exist for injectable compounded formulations specifically.

The oral options

Two oral semaglutide options exist in the telehealth market right now.

Rybelsus (oral semaglutide, Novo Nordisk) is the only FDA-approved oral GLP-1. It's approved for type 2 diabetes management, not specifically for weight loss. Some providers prescribe it off-label for weight loss, and studies suggest it may help with weight reduction, though the evidence base for weight loss specifically is more limited than for injectable Wegovy.

Rybelsus requires a strict fasting protocol: take it first thing in the morning with no more than 4 ounces (120mL) of water, then wait at least 30 minutes before eating, drinking anything other than water, or taking other medications (Rybelsus prescribing information, FDA.gov). This protocol matters because oral semaglutide has low bioavailability — as low as 0.4% to 1% of the dose is absorbed. The fasting window is necessary to maximize absorption. Skipping or shortening it can reduce how much of the medication actually reaches your bloodstream.

Oral compounded semaglutide was available through select telehealth providers until early 2026, when the FDA resolved the semaglutide shortage designation and most providers discontinued compounded oral offerings. As of April 2026, availability through major telehealth platforms is limited. Like compounded injectable semaglutide, oral compounded semaglutide contains the same active ingredient as brand-name products but is not FDA-approved as a finished product. Compounded oral formulations are even less studied than compounded injectables. The absorption considerations that apply to Rybelsus apply here as well — bioavailability limitations are a function of the molecule, not just the brand.

Because oral absorption is significantly lower than subcutaneous injection, the dose required for comparable effect is higher. For reference, Rybelsus doses range from 3mg to 14mg daily, while injectable Wegovy tops out at 2.4mg weekly. That dose gap reflects the bioavailability difference between the two delivery routes.

Head-to-head comparison

	Injectable GLP-1	Oral GLP-1
Efficacy evidence	Extensive — multiple large RCTs for brand-name injectables	More limited — especially for weight loss specifically
Convenience	Weekly dosing; requires needle	Daily dosing; no needle, but strict fasting protocol required
Cost	Brand-name: $299–$1,349/mo; compounded: $149–$449/mo	Rybelsus: ~$900+/mo list price; oral compounded: limited availability as of April 2026
Availability	Widely available across telehealth providers	Fewer providers offer oral options
FDA approval	Brand-name: approved for weight loss or T2D; compounded: not approved as finished product	Rybelsus: approved for T2D only; oral compounded: not FDA-approved as finished product
Dosing requirements	Inject once weekly; refrigerate medication	Take daily, 30+ min before food, with 4oz water only

Which should you choose?

The honest answer is that most clinical evidence for GLP-1 efficacy comes from injectable trials. If meaningful weight loss is the goal, injectables have a stronger evidence base. But the oral format is genuinely more convenient for many people, and convenience affects adherence.

On the needle concern: Many people who are hesitant about injections find the reality much easier than they imagined. GLP-1 auto-injector pens use a very fine, short needle. You inject into the fatty tissue of the abdomen or thigh — not a vein. It's not the same experience as a blood draw or IV. If needle anxiety is your main reason for considering oral, it may be worth trying an injectable first. Most providers can help you work through technique.

When oral makes sense: If you've genuinely tried injectables and can't tolerate them, or if the convenience of a daily pill outweighs the fasting requirement, oral is a reasonable option to discuss with your provider. FDA-approved Rybelsus is available through many telehealth platforms. Oral compounded semaglutide availability has narrowed since early 2026 following the FDA shortage resolution — verify with your provider whether it's currently available in your state.

On cost: Rybelsus (FDA-approved oral) typically runs $900+/month at list price, though insurance may cover it. Oral compounded semaglutide is less widely available than it was in 2024–2025. If an oral format is important to you, your provider can advise on current options.

Whatever format you're considering, consult your healthcare provider before starting any GLP-1 medication. They can factor in your medical history, medication tolerance, and specific weight loss goals.

Providers worth considering

Hims offers brand-name Wegovy (injectable) through its Novo Nordisk partnership, starting at $199/month for the medication plus a $149/month membership. Hims discontinued oral compounded semaglutide in Q1 2026 following FDA and legal pressure, though it remains a strong option for brand-name injectable semaglutide.

For injectable-focused programs with strong clinical support, Found offers 13 medications including compounded and brand-name injectables, plus a full behavioral coaching program.

GLP-1 medications require a prescription from a licensed healthcare provider. Compounded medications, including oral compounded semaglutide, are not FDA-approved as finished products. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.